EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer

Manh-Cuong Vo, Van-Tan Nguyen, Van-Dinh-Huan Tran, Hyung-Joo Oh, Sung-Hoon Jung, Woo Kyun Bae, Je-Jung Lee, In-Jae Oh

Cancer Immunology, Immunotherapy · 08.03.2025 · 74 (4)

DOI: 10.1007/s00262-025-03997-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 08.03.2025. Verfasst von Manh-Cuong Vo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Research and Development, Duy Tan University, Danang, Vietnam. Hauptthemen laut MEDLINE: Killer Cells, Natural, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Humanized, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite an initial response to platinum-based chemotherapy, most patients with extensive stage of small cell lung cancer (SCLC) have a poor prognosis due to recurrence. Additionally, the benefit of immune checkpoint inhibitors is more modest than non-small cell lung cancer. Natural killer (NK) cells can directly eliminate cancer cells without prior sensitization; this is largely governed by inflammatory cytokines, which serve as killing signals to cancer cells. Here, we investigated whether the combination of NK cells plus atezolizumab, a fully humanized monoclonal antibody that specifically targets the protein programmed death-ligand 1 (PD-L1), has a synergistic effect against SCLC. NK cells were expanded and activated using irradiated K562 feeder cells in the presence of interleukin (IL)-2/IL-15/IL-21/41BB ligand for 14 days. Expanded and activated NK cells (eNK) were combined with atezolizumab and used to treat SCLC cells in both in vitro and in vivo studies. The results revealed increased PD-L1 expression in SCLC cells after the eNK challenge. eNK cells plus atezolizumab demonstrated increased cytotoxicity toward target SCLC cells, as evidenced by increased interferon-γ and tumor necrosis factor-α production, and higher levels of SCLC stem cell (CD44+CD90+) suppression. Combined treatment with eNK and atezolizumab more effectively inhibited SCLC tumor growth and significantly prolonged the survival of treated mice. Our findings revealed that combining eNK with atezolizumab strongly increased cytotoxicity, significantly inhibited SCLC tumor growth, and prolonged the survival of treated mice. These results provide a framework for developing a more advanced immunotherapeutic modality for future clinical trials for patients with SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalSmall Cell Lung CarcinomaAntibodies, Monoclonal, HumanizedLung NeoplasmsAnimalsHumansMiceXenograft Model Antitumor AssaysFemaleCombined Modality TherapyB7-H1 AntigenCell Line, Tumor

Stichwörter der Autor:innen

Anti-PD-L1AtezolizumabCombination therapyNK cellsSmall cell lung cancer

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedB7-H1 Antigen

Autor:innen und Institutionen

  • Institute of Research and Development, Duy Tan University, Danang, Vietnam.
  • VaxCell-Biotherapeutics, Hwasun, South Korea.
  • Immunotherapy Innovation Center, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
  • Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, 322 Seoyang-Ro, Hwasun-Eup, Hwasun-gun, Jeollanam-do, 58128, Republic of Korea.
  • Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, 322 Seoyang-Ro, Hwasun-Eup, Hwasun-gun, Jeollanam-do, 58128, Republic of Korea. droij@chonnam.ac.…

Förderung

  • the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT)

Zitieren

APA

Vo, M. C., Nguyen, V. T., Tran, V. D., Oh, H. J., Jung, S. H., Bae, W. K., Lee, J. J., & Oh, I. J. (2025). Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer. Cancer Immunology, Immunotherapy, 74(4). https://doi.org/10.1007/s00262-025-03997-2

Vancouver

Vo MC, Nguyen VT, Tran VD, Oh HJ, Jung SH, Bae WK, et al. Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer. Cancer Immunology, Immunotherapy. 2025;74(4). doi:10.1007/s00262-025-03997-2

BibTeX
@article{Vo2025,
  author = {Vo, Manh-Cuong and Nguyen, Van-Tan and Tran, Van-Dinh-Huan and Oh, Hyung-Joo and Jung, Sung-Hoon and Bae, Woo Kyun and Lee, Je-Jung and Oh, In-Jae},
  title = {Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {4},
  doi = {10.1007/s00262-025-03997-2}
}
Kostenlos starten →